Merge Healthcare Incorporated (NASDAQ: MRGE), a leading provider of clinical systems and innovations that seek to transform healthcare, today announced that Worldwide Clinical Trials, Inc. has selected Merge’s eClinicalOS® solution to accelerate study startup, streamline electronic data capture (EDC), and maximize operational efficiency across its Phase I-IV studies.
“We are always looking for ways to increase efficiency and improve study timelines,” explained Graham Downing, Vice President of Global Data, Statistics and Technology at Worldwide Clinical Trials, Inc. “Adding a system to our solutions portfolio that would enable rapid study database set-up, efficiencies in data processing, and that incorporated status and metrics reporting was key.”
“The implementation of eClinicalOS at Worldwide Clinical Trials represents an opportunity to increase awarded studies”, Downing continued. “The straight-forward interface and user experience allows studies to be built and deployed in a fraction of the time of other tools. With eClinicalOS, we’ve seen a significant improvement in our study start-up timelines and processing efforts allowing us to pass on cost savings to our clients. This is a valuable further solution that we offer to our sponsor projects.”
“Merge eClinicalOS has the flexibility to support trials in all phases. Worldwide Clinical Trials initially selected eClinicalOS as a cost-effective, easy-to-use system that would accelerate startup and streamline management of their clients’ Phase I trials,” said Justin Dearborn, President of Merge Healthcare. “They are now implementing eClinicalOS for other phases and trials. We are pleased to have been selected as a provider for their global clinical trial needs, and look forward to working closely with them as they expand their use of eClinicalOS.”
Merge eClinicalOS provides end-to-end study support through a single, easy-to-use interface so clients can manage and run studies more efficiently than ever before. It delivers built-in study templates, libraries and reports to help users create studies quickly and manage them effectively without technical assistance. Merge eClinicalOS works for the largest and smallest of studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. It also has the scalability to grow if a trial increases in size, number or complexity.
About Merge Healthcare
Merge is a leading provider of clinical systems and innovations that seek to transform healthcare. Merge’s enterprise and cloud-based solutions for image intensive specialties provide access to any image, anywhere, any time. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health. With solutions that are used by providers and consumers and include more than 20 years of innovation, Merge is helping to reduce costs and improve the quality of healthcare worldwide. For more information, visit merge.com.
About Worldwide Clinical Trials, Inc.
Worldwide Clinical Trials is a global, full-service contract research organization (CRO) that is medically and scientifically focused on central nervous system, cardiovascular, chronic inflammatory, respiratory and oncology disorders. Worldwide Clinical Trials delivers quality clinical trials with leading edge science and medicine to help clients think through design, methodology and regulatory issues that are unique to every development program. Worldwide Clinical Trials provides highly focused CRO services in all phases of research. For more information, visit www.ctrials.com.
Cautionary Notice Regarding Forward-Looking Statements
The matters discussed in this news release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words “will,” “believes,” “intends,” “anticipates,” “expects” and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.